Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Operating Leases (2019 - 2021)

Cyclerion Therapeutics (CYCN) has disclosed Operating Leases for 3 consecutive years, with $38.1 million as the latest value for Q1 2021.

  • For Q1 2021, Operating Leases fell 19.1% year-over-year to $38.1 million; the TTM value through Mar 2021 reached $38.1 million, down 19.1%, while the annual FY2020 figure was $38.9 million, 44.78% down from the prior year.
  • Operating Leases hit $38.1 million in Q1 2021 for Cyclerion Therapeutics, down from $38.9 million in the prior quarter.
  • Across five years, Operating Leases topped out at $72.4 million in Q2 2019 and bottomed at $38.1 million in Q1 2021.
  • Average Operating Leases over 3 years is $53.1 million, with a median of $46.7 million recorded in 2020.
  • Year-over-year, Operating Leases plummeted 44.78% in 2020 and then decreased 19.1% in 2021.
  • Cyclerion Therapeutics' Operating Leases stood at $70.5 million in 2019, then tumbled by 44.78% to $38.9 million in 2020, then dropped by 2.22% to $38.1 million in 2021.
  • According to Business Quant data, Operating Leases over the past three periods came in at $38.1 million, $38.9 million, and $39.8 million for Q1 2021, Q4 2020, and Q3 2020 respectively.